Cogent Biosciences Quarterly Cash Flow Statement
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.00+0.92 (+3.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences free cash flow
In the quarter ended Jun 30, 2026, Cogent Biosciences generated -$77.3 million of operating cash flow and spent $370,000 on capital expenditures. That left free cash flow of -$77.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -96.41M | -97.35M | -102.49M | -80.93M | -73.53M | -71.99M | -67.93M | -70.63M | -58.95M | -58.35M | -54.37M | -55.38M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 741.00K | 626.00K | 664.00K | 641.00K | 655.00K | 640.00K | 675.00K | 620.00K | 606.00K | 599.00K | 628.00K | 581.00K |
| Stock-Based Compensation | 17.11M | 16.91M | 15.75M | 10.60M | 9.72M | 10.01M | 9.98M | 10.36M | 10.01M | 9.39M | 8.85M | 8.76M |
| Change in Working Capital | -6.23M | 5.63M | -5.33M | -211.00K | 2.48M | 2.15M | -3.04M | 6.09M | -6.59M | 4.91M | 785.00K | 2.62M |
| Operating Cash Flow | -77.27M | -86.88M | -79.11M | -64.29M | -54.54M | -66.51M | -60.58M | -51.98M | -42.70M | -52.53M | -44.07M | -37.97M |
| Capital Expenditures | -370.00K | -449.00K | -811.00K | -65.00K | -131.00K | -547.00K | -75.00K | -280.00K | -148.00K | -70.00K | -315.00K | -121.00K |
| Investing Cash Flow | 14.28M | -36.46M | -322.77M | -155.05M | 8.91M | 69.38M | 61.67M | 60.19M | -84.63M | 1.04M | 10.49M | -90.54M |
| Debt Issued | — | — | 0 | 0 | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 2.96M | 52.54M | 588.67M | 217.37M | 47.23M | 24.97M | 26.00K | 624.00K | -256.00K | 214.06M | 0 | 1.00M |
| Net Change in Cash | -60.04M | -70.80M | 186.79M | -1.97M | 1.59M | 27.84M | 1.12M | 8.83M | -127.58M | 162.57M | -33.58M | -127.51M |
| Free Cash Flow | -77.64M | -87.33M | -79.92M | -64.35M | -54.67M | -67.06M | -60.65M | -52.26M | -42.85M | -52.60M | -44.38M | -38.09M |
This table shows 12 quarterly periods of Cogent Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow COGT's reporting calendar. What is a cash flow statement?